Holen Sie sich die Stockscreener-App
17.78
3.94%
-0.73
Handel nachbörslich:
17.78
Schlusskurs vom Vortag:
$18.51
Offen:
$17.78
24-Stunden-Volumen:
1.03M
Relative Volume:
1.05
Marktkapitalisierung:
$545.26M
Einnahmen:
$17.16M
Nettoeinkommen (Verlust:
$-163.62M
KGV:
-2.9243
EPS:
-6.08
Netto-Cashflow:
$-121.61M
1W Leistung:
-4.36%
1M Leistung:
+8.81%
6M Leistung:
-46.12%
1J Leistung:
-15.65%
1-Tages-Spanne:
$17.11
$18.74
1-Wochen-Bereich:
$17.11
$19.82
52-Wochen-Spanne:
$12.21
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
Firmenname
Anaptysbio Inc
Sektor
Branche
Telefon
858-362-6295
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Vergleichen Sie ANAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
17.78 | 545.26M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-03-12 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-02-26 | Eingeleitet | BTIG Research | Buy |
| 2024-02-21 | Eingeleitet | Stifel | Buy |
| 2024-02-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-13 | Herabstufung | Truist | Buy → Hold |
| 2022-09-01 | Eingeleitet | Raymond James | Outperform |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-03-16 | Hochstufung | Truist | Hold → Buy |
| 2021-03-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-10-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2019-11-08 | Herabstufung | SunTrust | Buy → Hold |
| 2019-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-04-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Bestätigt | Stifel | Buy |
| 2018-03-06 | Bestätigt | Stifel | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2018-01-23 | Bestätigt | Credit Suisse | Outperform |
| 2017-11-15 | Eingeleitet | SunTrust | Buy |
| 2017-11-09 | Eingeleitet | Jefferies | Buy |
| 2017-10-11 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
AnaptysBio, Inc.'s (NASDAQ:ANAB) Price Is Right But Growth Is Lacking After Shares Rocket 30% - simplywall.st
AnaptysBio (NASDAQ:ANAB) Trading 2.5% HigherTime to Buy? - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Stock Holdings Increased by Swiss National Bank - Defense World
How to Take Advantage of moves in (ANAB) - news.stocktradersdaily.com
AnaptysBio (NASDAQ:ANAB) Shares Gap UpShould You Buy? - MarketBeat
Charles Schwab Investment Management Inc. Acquires 5,733 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio (NASDAQ:ANAB) Trading Down 4.1%Should You Sell? - MarketBeat
AnaptysBio (NASDAQ:ANAB) to Repurchase $75.00 million in Stock - MarketBeat
Bank of New York Mellon Corp Sells 1,972 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Leerink Partners Sticks to Their Buy Rating for AnaptysBio (ANAB) - The Globe and Mail
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last? - MSN
AnaptysBio (NASDAQ:ANAB) to Repurchase $75.00 million in Shares - Defense World
AnaptysBio Shares Jump on Buyback Program Authorization - MarketWatch
Crude Oil Gains 1%; US Composite PMI Surges In March - Benzinga
Anaptys Announces Stock Repurchase Plan - GlobeNewswire
AnaptysBio authorizes $75 million stock buyback plan By Investing.com - Investing.com South Africa
Anaptys announces $75 million stock repurchase plan - MSN
AnaptysBio Announces $75 Mln Stock Repurchase Plan - Nasdaq
AnaptysBio stock rises following stock repurchase plan By Investing.com - Investing.com Canada
Intuitive Machines Posts Q4 Results, Joins Tesla, AnaptysBio, Coherent And Other Big Stocks Moving Higher On Monday - Benzinga
AnaptysBio Approves $75 Million Buyback Plan; Shares Rise -March 24, 2025 at 09:50 am EDT - Marketscreener.com
AnaptysBio authorizes $75 million stock buyback plan - Investing.com India
AnaptysBio, Inc. Authorizes $75 Million Stock Repurchase Plan - Nasdaq
AnaptysBio (NASDAQ:ANAB) Trading Up 4.4%Still a Buy? - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
AlphaQuest LLC Purchases 4,237 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Position Raised by Victory Capital Management Inc. - MarketBeat
Victory Capital Management Inc. Purchases 97,200 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks - markets.businessinsider.com
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $42.00 - MarketBeat
Rhumbline Advisers Grows Position in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
HC Wainwright Reaffirms Neutral Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
When (ANAB) Moves Investors should Listen - Stock Traders Daily
AnaptysBio (NASDAQ:ANAB) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - Defense World
23,497 Shares in AnaptysBio, Inc. (NASDAQ:ANAB) Purchased by Y Intercept Hong Kong Ltd - MarketBeat
Leerink Partnrs Weighs in on AnaptysBio FY2029 Earnings - MarketBeat
AnaptysBio (ANAB) to Release Quarterly Earnings on Monday - MarketBeat
AnaptysBio: A Shadow Of Its Former Self (NASDAQ:ANAB) - Seeking Alpha
Finanzdaten der Anaptysbio Inc-Aktie (ANAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):